The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. [electronic resource]
Producer: 20141121Description: 317-26 p. digitalISSN:- 1873-2496
- Aged
- Antineoplastic Agents -- administration & dosage
- Blotting, Western
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Drug Synergism
- Female
- Humans
- Imidazoles -- administration & dosage
- Immunohistochemistry
- Indoles -- administration & dosage
- Lapatinib
- Male
- Purines -- administration & dosage
- Quinazolines -- administration & dosage
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Tissue Array Analysis
- Triazines -- administration & dosage
- Urinary Bladder Neoplasms -- pathology
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.